Search Results

Corporate Score 85 Bullish

Hims & Hers Soars Nearly 50% on Deal With Novo Nordisk to Resolve Drug Dispute

Mar 09, 2026 09:45 UTC
HIMS, NVO, XLV
Short term

Hims & Hers Inc. (HIMS) surged almost 50% in premarket trading after reports confirmed a resolution to its legal and commercial dispute with Novo Nordisk (NVO), culminating in a new partnership. The development signals a major strategic shift in the digital health and weight-loss pharmaceutical space.

  • HIMS shares surged nearly 50% in premarket trading on March 9, 2026
  • The rise followed confirmation of a partnership with Novo Nordisk (NVO) to end a dispute over weight-loss drug access
  • Hims & Hers reported $287 million in revenue for fiscal 2024
  • The agreement enables HIMS to expand access to Novo Nordisk’s GLP-1 therapies including Wegovy and Ozempic
  • The U.S. weight-loss drug market is valued at over $20 billion and expected to grow at 12% CAGR through 2030
  • Novo Nordisk (NVO) gained 2.1% in early trading, and healthcare ETF XLV rose 0.6%

Hims & Hers Inc. (HIMS) saw its shares climb nearly 50% in premarket trading on Monday, following reports of a settlement and partnership with Novo Nordisk (NVO), the Danish pharmaceutical giant known for its GLP-1 weight-loss drugs. The resolution ends months of tension over access to prescription weight-loss medications, which had been a key point of contention between the two companies. The new agreement is expected to enable Hims & Hers to expand its digital health platform with broader access to Novo Nordisk’s branded therapies, including Wegovy and Ozempic, through a co-branded prescription network. The move underscores a pivotal moment for the telehealth and consumer health sector, where demand for weight-loss treatments has surged while regulatory and supply chain challenges persist. Hims & Hers, which reported revenue of $287 million in fiscal 2024, now stands to strengthen its position in the $20 billion-plus weight-loss drug market, which is projected to grow at a 12% CAGR through 2030. The partnership with NVO also signals a shift toward greater collaboration between digital-first health platforms and traditional pharmaceutical firms. The stock’s dramatic rise reflects strong investor confidence in the new commercial alignment. HIMS traded at $21.30 premarket, up from $14.30 the previous close. Meanwhile, Novo Nordisk (NVO) rose 2.1% in early trading, suggesting market approval of the deal’s structure. The healthcare sector ETF (XLV) also gained 0.6% as investors viewed the development as a positive signal for specialty pharmaceutical partnerships and digital health integration.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 65 Bullish

Berkshire Hathaway Proxy Filing Hints at Share Buyback Resumption

Mar 14, 13:03

Score 25

You Won't Believe How Much Money Berkshire Hathaway Gets From Coca-Cola Dividends

Mar 14, 12:29

Score 35 Bearish

How Much Lower Can Opendoor Technologies Stock Go?

Mar 14, 12:01

Score 85 Bullish

Oracle Reveals $2.2 Billion Investment In TikTok's US Business After ByteDance Divestment, Holds 15% Stake

Mar 14, 12:00

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Intelligence Terminal AI Assistant Trading Challenge Analysis Market News Pricing
Sign In Get Started
Home
Terminal
AI
Markets
Profile